Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Efil Bioscience Inc. maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio has 2 pending office actions. These 2 pending office actions are assigned to 2 distinct examiners, providing a distribution of the current workload across different reviewers. This ensures that each of the 2 pending office actions receives an independent assessment from a different examiner.
Prosecution activity occurs within 2 distinct art units. FIEBIG, RUSSELL G is the busiest examiner, holding 1 busiest examiner pending office action. With 2 pending office actions, 2 distinct examiners, and 2 distinct art units, the company's current patent matters are distributed across different examiners and technical units. This indicates that the company's Biotechnology & Pharmaceuticals research falls under the jurisdiction of 2 distinct art units. The use of 2 distinct examiners for the 2 pending office actions means that each application is being evaluated separately. This requires the company to address the specific technical and procedural requirements of 2 different examination environments within the patent office, providing multiple perspectives on their intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18739065 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, AND IMPROVING RESPIRATORY SYMPTOMS | FIEBIG, RUSSELL G | — |
| 18501740 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | D' AMBROSIO, THEA | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18739065 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, AND IMPROVING RESPIRATORY SYMPTOMS | FIEBIG, RUSSELL G | 1655 | §103 | Non-Final OA | — | Pending | Jun 10, 2024 |
| 18501740 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | D' AMBROSIO, THEA | 1654 | §103DP | Final Rejection | — | Pending | Nov 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEfil Bioscience Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Russell G Fiebig has the most, with 1 of Efil Bioscience Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
